220 related articles for article (PubMed ID: 3257774)
1. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes.
Russell DG; Alexander J
J Immunol; 1988 Feb; 140(4):1274-9. PubMed ID: 3257774
[TBL] [Abstract][Full Text] [Related]
2. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization.
Kahl LP; Scott CA; Lelchuk R; Gregoriadis G; Liew FY
J Immunol; 1989 Jun; 142(12):4441-9. PubMed ID: 2786033
[TBL] [Abstract][Full Text] [Related]
3. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes.
Scott P; Pearce E; Natovitz P; Sher A
J Immunol; 1987 Jul; 139(1):221-7. PubMed ID: 3495599
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic immunization against experimental leishmaniasis. V. Mechanism of the anti-protective blocking effect induced by subcutaneous immunization against Leishmania major infection.
Liew FY; Singleton A; Cillari E; Howard JG
J Immunol; 1985 Sep; 135(3):2102-7. PubMed ID: 3160786
[TBL] [Abstract][Full Text] [Related]
5. Vaccination of different strains of mice against cutaneous leishmaniosis: usefulness of membrane antigens encapsulated into liposomes by intraperitoneal and subcutaneous administration.
Lezama-Dávila CM
Arch Med Res; 1997; 28(1):47-53. PubMed ID: 9078587
[TBL] [Abstract][Full Text] [Related]
6. Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes.
Ali N; Afrin F
J Parasitol; 1997 Feb; 83(1):70-5. PubMed ID: 9057699
[TBL] [Abstract][Full Text] [Related]
7. Protection against Leishmania major in BALB/c mice by adoptive transfer of a T cell clone recognizing a low molecular weight antigen released by promastigotes.
Scott P; Caspar P; Sher A
J Immunol; 1990 Feb; 144(3):1075-9. PubMed ID: 2295814
[TBL] [Abstract][Full Text] [Related]
8. Histopathologic changes induced by vaccination in experimental cutaneous leishmaniasis of BALB/c mice.
Barral-Netto M; de Freitas LA; Andrade ZA
Am J Pathol; 1987 May; 127(2):271-8. PubMed ID: 3495185
[TBL] [Abstract][Full Text] [Related]
9. [Independence of the delayed hypersensitivity response from protection against Leishmania mexicana pifanoi].
Pérez HA; De la Rora M
Acta Cient Venez; 1986; 37(5):542-6. PubMed ID: 2966535
[No Abstract] [Full Text] [Related]
10. Antigen-reactive gamma delta T cells in human leishmaniasis.
Russo DM; Armitage RJ; Barral-Netto M; Barral A; Grabstein KH; Reed SG
J Immunol; 1993 Oct; 151(7):3712-8. PubMed ID: 8376802
[TBL] [Abstract][Full Text] [Related]
11. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes.
Badiee A; Jaafari MR; Khamesipour A
Exp Parasitol; 2007 Feb; 115(2):127-34. PubMed ID: 16979165
[TBL] [Abstract][Full Text] [Related]
12. Immunoregulatory pathways in murine leishmaniasis: different regulatory control during Leishmania mexicana mexicana and Leishmania major infections.
Alexander J; Kaye PM
Clin Exp Immunol; 1985 Sep; 61(3):674-82. PubMed ID: 3907906
[TBL] [Abstract][Full Text] [Related]
13. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953
[TBL] [Abstract][Full Text] [Related]
14. Genetic background influences immune responses and disease outcome of cutaneous L. mexicana infection in mice.
Rosas LE; Keiser T; Barbi J; Satoskar AA; Septer A; Kaczmarek J; Lezama-Davila CM; Satoskar AR
Int Immunol; 2005 Oct; 17(10):1347-57. PubMed ID: 16141242
[TBL] [Abstract][Full Text] [Related]
15. CTL responses to Leishmania mexicana gp63-cDNA vaccine in a murine model.
Ali SA; Rezvan H; McArdle SE; Khodadadi A; Asteal FA; Rees RC
Parasite Immunol; 2009 Jul; 31(7):373-83. PubMed ID: 19527453
[TBL] [Abstract][Full Text] [Related]
16. Immunization with Leishmania-specific T cell not B cell lines or hybridomas can modulate the response of susceptible mice infected with viable parasites.
Gorczynski RM
J Immunol; 1987 Nov; 139(9):3070-5. PubMed ID: 3499464
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant effect of Taenia crassiceps glycans against leishmanial antigens in mice infected with Leishmania mexicana.
Dissanayake S; Shahin A; Ameen AM
Mol Immunol; 2005 Aug; 42(12):1495-502. PubMed ID: 15950742
[TBL] [Abstract][Full Text] [Related]
18. DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice.
Ahmed SB; Touihri L; Chtourou Y; Dellagi K; Bahloul C
Vaccine; 2009 Jan; 27(1):99-106. PubMed ID: 18951941
[TBL] [Abstract][Full Text] [Related]
19. The involvement of the major surface glycoprotein (gp63) of Leishmania promastigotes in attachment to macrophages.
Russell DG; Wilhelm H
J Immunol; 1986 Apr; 136(7):2613-20. PubMed ID: 3950420
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
